The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures
J Galon, HK Angell, D Bedognetti, FM Marincola - Immunity, 2013 - cell.com
Numerous analyses of large patient cohorts identified specific patterns of immune activation
associated with patient survival. We established these as the immune contexture …
associated with patient survival. We established these as the immune contexture …
Immune responses and immunopathology in acute and chronic viral hepatitis
Hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) are responsible
for most cases of viral hepatitis. Infection by each type of virus results in a different typical …
for most cases of viral hepatitis. Infection by each type of virus results in a different typical …
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
RE Lanford, ES Hildebrandt-Eriksen, A Petri… - Science, 2010 - science.org
The liver-expressed microRNA-122 (miR-122) is essential for hepatitis C virus (HCV) RNA
accumulation in cultured liver cells, but its potential as a target for antiviral intervention has …
accumulation in cultured liver cells, but its potential as a target for antiviral intervention has …
[HTML][HTML] Innate and adaptive immune responses in HCV infections
MH Heim, R Thimme - Journal of hepatology, 2014 - Elsevier
Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of
chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a …
chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a …
Current and future therapies for hepatitis C virus infection
Current and Future Therapies for Hepatitis C Virus Infection | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Skip to main content The New England Journal of Medicine homepage Advanced Search …
[HTML][HTML] Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
C Hézode, N Forestier, G Dusheiko… - … England Journal of …, 2009 - Mass Medical Soc
Background In patients with chronic infection with hepatitis C virus (HCV) genotype 1,
treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained …
treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained …
Цитокины в патогенезе и лечении заболеваний человека
АС Симбирцев - 2018 - elibrary.ru
В монографии приведены сведения по роли цитокинов в регуляции физиологических
процессов, защитных реакций организма и в патогенезе иммунопатологических …
процессов, защитных реакций организма и в патогенезе иммунопатологических …
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C
M Honda, A Sakai, T Yamashita, Y Nakamoto… - Gastroenterology, 2010 - Elsevier
BACKGROUND & AIMS: Multiple viral and host factors are related to the treatment response
to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance …
to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance …
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
EG Meissner, D Wu, A Osinusi, D Bon… - The Journal of …, 2014 - Am Soc Clin Investig
BACKGROUND. Hepatitis C virus (HCV) infects approximately 170 million people worldwide
and may lead to cirrhosis and hepatocellular carcinoma in chronically infected individuals …
and may lead to cirrhosis and hepatocellular carcinoma in chronically infected individuals …
[PDF][PDF] IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C
Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been
associated with sustained virological response (SVR) rates in patients with chronic hepatitis …
associated with sustained virological response (SVR) rates in patients with chronic hepatitis …